Novartis AG on Monday said that the 3rd phase of its Ruskovit study did not meet its primary decision to reduce the number of Kovit-19 patients admitted to hospital with complications.
In the quality of maintenance treatment, ruxolitin did not significantly reduce the number of Kovit-19 patients in the hospital, causing serious complications including death, respiratory distress, mechanical ventilation or admission to the intensive care unit, medication. Said the giant.
“The trial did not show a clinically relevant benefit between the secondary and probationary points, including the mortality rate and recovery time by the 29th,” Novartis said.
Write to Olivia Bogault at olivia.bugaultியாwsj.com